A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 743 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR “White Bagging” Harmful to Patients, Requires Them to Use Insurance-Approved Formulary... July 2, 2021 Targeted Therapy for Claudin-18.2 and Combined PD-1 and TIGIT Immunotherapy for... November 6, 2023 News digest – targeted radiation beam, precision medicine and our early... October 17, 2020 Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment... August 2, 2023 Load more HOT NEWS ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ Opinion: What should the cancer agenda look like for the new... The award-winning team transforming breast cancer treatment Disease in a dish: Mini-gut organoids and the challenges of bowel...
